DNA damage and metabolic mechanisms of cancer drug resistance
作者机构：The Ken&Ruth Davee Department of NeurologyLou and Jean Malnati Brain Tumor Institute at Northwestern MedicineRobert H.Lurie Comprehensive Cancer Centerand Simpson Querry Institute for EpigeneticsNorthwestern UniversityFeinberg School of Medicine303 E Superior StChicagoIL 60611USA
出 版 物：《Cancer Drug Resistance》 (癌症耐药（英文）)
年 卷 期：2022年第5卷第2期
页 面：368-379页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：Malnati Brain Tumor Institute of Northwestern Medicine National Institutes of Health, NIH, (K00 CA234799, NS115403) National Institutes of Health, NIH
主 题：metabolism damage drugs
摘 要：Cancer drug resistance is one of the main barriers to overcome to ensure durable treatment *** many pivotal advances have been made in first combination therapies,then targeted therapies,and now broadening out to immunomodulatory drugs or metabolic targeting compounds,drug resistance is still ultimately universally *** this brief review,we will discuss different strategies that have been used to fight drug resistance from synthetic lethality to tumor microenvironment modulation,focusing on the DNA damage response and tumor metabolism both within tumor cells and their surrounding *** this way,with a better understanding of both targetable mutations in combination with the metabolism,smarter drugs may be designed to combat cancer drug resistance.
维普期刊数据库